Low-grade serous ovarian cancer: State of the science

Brian Slomovitz, Charlie Gourley, Mark S. Carey, Anais Malpica, Ie Ming Shih, David Huntsman, Amanda N. Fader, Rachel N. Grisham, Matthew Schlumbrecht, Charlotte C. Sun, Jane Ludemann, Gail Austin Cooney, Robert Coleman, Anil K. Sood, Haider Mahdi, Kwong K. Wong, Allan Covens, David M. O'Malley, Fabrice Lecuru, Lauren P. CobbThomas A. Caputo, Taymaa May, Marilyn Huang, John Siemon, Marta Llauradó Fernández, Isabelle Ray-Coquard, David M. Gershenson

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations

Abstract

In January 2019, a group of basic, translational, and clinical investigators and patient advocates assembled in Miami, Florida, to discuss the current state of the science of low-grade serous carcinoma of the ovary or peritoneum–a rare ovarian cancer subtype that may arise de novo or following a diagnosis of serous borderline tumor. The purpose of the conference was to review current knowledge, discuss ongoing research by established researchers, and frame critical questions or issues for future directions. Following presentations and discussions, the primary objective was to initiate future collaborations, uniform database platforms, laboratory studies, and clinical trials to better understand this disease and to advance clinical care outside the boundaries of single academic institutions. This review summarizes the state of the science in five principal categories: epidemiology and patient outcomes, pathology, translational research, patient care and clinical trials, and patients' perspective.

Original languageEnglish (US)
Pages (from-to)715-725
Number of pages11
JournalGynecologic oncology
Volume156
Issue number3
DOIs
StatePublished - Mar 2020

Keywords

  • Epithelial ovarian cancer
  • Low-grade serous carcinoma of the ovary
  • Low-grade serous carcinoma of the peritoneum

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Fingerprint Dive into the research topics of 'Low-grade serous ovarian cancer: State of the science'. Together they form a unique fingerprint.

Cite this